Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Culture, Healing, Health & Wellness

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

Breaking News

4 Feb 2025

A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements

Enveric Biosciences has entered into a licensing agreement with Restoration Biologics to develop and commercialize cannabinoid-COX-2 conjugate compounds, promising a new frontier in joint disease treatment. This partnership could redefine...

By Madison Roberts

Healing

6 Jan 2025

Healing Sexual Assault Trauma with Psychedelic Journeys: Potentials and Pitfalls

The use of psychedelic therapy to treat sexual assault trauma represents a groundbreaking shift in mental healthcare. By facilitating profound emotional breakthroughs, fostering reconnection to the body, and offering new...

By Madison Roberts

Industry

1 Jan 2025

The Psychedelic Industry in 2025: A New Era of Healing and Transformation

The psychedelic industry is poised for groundbreaking advancements in 2025, from new clinical applications to state-level regulatory frameworks. Experts highlight the potential for treating PTSD, depression, and addiction while addressing...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

21 Nov 2024

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

After years of regulatory hurdles, MAPS has secured FDA clearance to study cannabis for PTSD in a real-world context. This groundbreaking trial focuses on veterans and aims to provide high-quality...

By Madison Roberts

Culture

18 Nov 2024

Introduction to Jill Sitnick: A Courageous Journey from Healing to Advocacy

Jill Sitnick’s journey with MDMA-assisted therapy took her from the depths of PTSD to a place of healing and advocacy. In this powerful account, she shares how the therapy helped...

By Madison Roberts

Industry

16 Nov 2024

atai Life Sciences and Enveric Biosciences Report Q3 2024 Results

In their Q3 2024 financial updates, atai Life Sciences and Enveric Biosciences demonstrate fiscal discipline and innovation. atai maintains funding into 2026 with a promising psychedelic therapy pipeline, while Enveric...

By Madison Roberts

Press Releases

13 Nov 2024

Enveric and MycoMedica’s New Licensing Agreement Marks a Strategic Shift in Mental Health Treatment

In a groundbreaking collaboration, Enveric Biosciences has signed a licensing agreement with MycoMedica Life Sciences, granting exclusive rights to develop and commercialize its psilocin-based drug candidate, EB-002. This deal, potentially...

By Madison Roberts

Industry

6 Nov 2024

Enveric Biosciences Expands Patent Portfolio

Enveric Biosciences has expanded its intellectual property portfolio with five new U.S. patents for compounds in its EVM301 portfolio, positioning the company as a leader in innovative treatments for neuropsychiatric...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

WordPress Ads